Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 3b Open label Study Evaluating the Long term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects Ages 6 Years and Older Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

    Summary
    EudraCT number
    2020-001404-42
    Trial protocol
    GB   DE   DK   NL   FR  
    Global end of trial date
    24 Mar 2023

    Results information
    Results version number
    v2(current)
    This version publication date
    25 May 2024
    First version publication date
    08 Oct 2023
    Other versions
    v1
    Version creation reason
    • New data added to full data set
    Final result is updated in draft

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    VX20-445-119
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04545515
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Vertex Pharmaceuticals Incorporated
    Sponsor organisation address
    50 Northern Avenue , Boston, Massachusetts, United States,
    Public contact
    Medical Monitor, Vertex Pharmaceuticals Incorporated, medicalinfo@vrtx.com
    Scientific contact
    Medical Monitor, Vertex Pharmaceuticals Incorporated, medicalinfo@vrtx.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    20 Apr 2023
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    24 Mar 2023
    Global end of trial reached?
    Yes
    Global end of trial date
    24 Mar 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To evaluate the long term safety and tolerability of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) in subjects with Cystic Fibrosis (CF)
    Protection of trial subjects
    The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the International Conference on Harmonization (ICH) Guideline for Good Clinical Practice (GCP).
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    11 Jan 2021
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Efficacy, Safety
    Long term follow-up duration
    23 Months
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 17
    Country: Number of subjects enrolled
    Switzerland: 12
    Country: Number of subjects enrolled
    Australia: 11
    Country: Number of subjects enrolled
    Canada: 13
    Country: Number of subjects enrolled
    Denmark: 3
    Country: Number of subjects enrolled
    France: 13
    Country: Number of subjects enrolled
    Germany: 31
    Country: Number of subjects enrolled
    Israel: 5
    Country: Number of subjects enrolled
    Netherlands: 7
    Country: Number of subjects enrolled
    Spain: 8
    Worldwide total number of subjects
    120
    EEA total number of subjects
    62
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    120
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    A total of 120 subjects from the parent study VX19-445-116 (NCT04353817) enrolled in this study.

    Period 1
    Period 1 title
    Overall Period
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Arm title
    ELX/TEZ/IVA
    Arm description
    Subjects 6 to less than <12 year of age and weighing <30 kilogram (kg) at Day 1 received ELX 100 milligram (mg)/TEZ 50 mg /IVA 75 mg as fixed dose combination (FDC) tablets in the morning and IVA as mono tablet in the evening and those weighing more than or equal to (≥) 30 kg at Day 1 received ELX 200 mg/TEZ 100 mg /IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 96 weeks. Doses were adjusted upward with subsequent changes in weight. Subjects ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 96 weeks.
    Arm type
    Experimental

    Investigational medicinal product name
    ELX/TEZ/IVA
    Investigational medicinal product code
    VX-445/VX-661/VX-770
    Other name
    elexacaftor/tezacaftor/ivacaftor
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received ELX/TEZ/IVA fixed dose combination (FDC), once daily in the morning.

    Investigational medicinal product name
    IVA
    Investigational medicinal product code
    VX-770
    Other name
    ivacaftor
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received IVA once daily in the evening.

    Number of subjects in period 1
    ELX/TEZ/IVA
    Started
    120
    Placebo-ELX/TEZ/IVA
    61 [1]
    ELX/TEZ/IVA-ELX/TEZ/IVA
    59 [2]
    Completed
    110
    Not completed
    10
         Adverse event
    1
         Withdrawal of consent (not due to AE)
    2
         Commercial drug is available for subject
    7
    Notes
    [1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
    Justification: Subjects from the Placebo group of the parent study VX19-445-116, who received ELX/TEZ/IVA during the current study VX20-445-119.
    [2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
    Justification: Subjects from the ELX/TEZ/IVA group of the parent study VX19-445-116, who continued to receive ELX/TEZ/IVA during the current study VX20-445-119.

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Overall Period
    Reporting group description
    Baseline data for the long-term safety analysis is based on the parent study baseline, which is defined as the most recent non-missing measurement collected before the first dose of study drug in the treatment period of parent study.

    Reporting group values
    Overall Period Total
    Number of subjects
    120 120
    Age categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    9.1 ( 1.7 ) -
    Gender categorical
    Units: Subjects
        Female
    69 69
        Male
    51 51
    Ethnicity
    Units: Subjects
        Hispanic or Latino
    1 1
        Not Hispanic or Latino
    90 90
        Not collected per local regulations
    29 29
    Race
    Units: Subjects
        White
    87 87
        Black or African American
    1 1
        Asian
    1 1
        American Indian or Alaska Native
    1 1
        Other
    1 1
        Not collected per local Regulations
    28 28
        Multiracial
    1 1

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    ELX/TEZ/IVA
    Reporting group description
    Subjects 6 to less than <12 year of age and weighing <30 kilogram (kg) at Day 1 received ELX 100 milligram (mg)/TEZ 50 mg /IVA 75 mg as fixed dose combination (FDC) tablets in the morning and IVA as mono tablet in the evening and those weighing more than or equal to (≥) 30 kg at Day 1 received ELX 200 mg/TEZ 100 mg /IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 96 weeks. Doses were adjusted upward with subsequent changes in weight. Subjects ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 96 weeks.

    Primary: Safety and Tolerability as Assessed by Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Close Top of page
    End point title
    Safety and Tolerability as Assessed by Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [1]
    End point description
    The Open-Label Safety Set (OL-SS) included all subjects who had received at least 1 dose of study drug in the Open label extension (OLE) study.
    End point type
    Primary
    End point timeframe
    From Baseline up to Week 100
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive statistics were planned. No statistical comparisons were planned for the primary safety endpoint.
    End point values
    ELX/TEZ/IVA
    Number of subjects analysed
    120
    Units: Subjects
        Subjects With TEAEs
    118
        Subjects With SAEs
    13
    No statistical analyses for this end point

    Secondary: Absolute Change From Parent Study Baseline in Sweat Chloride (SwCl)

    Close Top of page
    End point title
    Absolute Change From Parent Study Baseline in Sweat Chloride (SwCl)
    End point description
    Sweat samples were collected using an approved collection device. The OL Full Analysis Set (OL-FAS) is defined as all enrolled subjects who have received at least 1 dose of study drug in the open-label extension study. Data were planned to be presented as per parent study reporting groups (i.e., Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA). Here, “n” signifies subjects who were evaluable in the specified parent study reporting group at OL Week 96.
    End point type
    Secondary
    End point timeframe
    From Parent Study Baseline to Week 96
    End point values
    ELX/TEZ/IVA
    Number of subjects analysed
    98
    Units: millimole per liter (mmol/L)
    least squares mean (standard error)
        Placebo-ELX/TEZ/IVA (n=52)
    -57.3 ( 2.2 )
        ELX/TEZ/IVA-ELX/TEZ/IVA (n=46)
    -57.5 ( 2.3 )
    No statistical analyses for this end point

    Secondary: Absolute Change From Parent Study Baseline in Lung Clearance Index 2.5 (LCI2.5)

    Close Top of page
    End point title
    Absolute Change From Parent Study Baseline in Lung Clearance Index 2.5 (LCI2.5)
    End point description
    The LCI2.5 index is the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting values and is calculated by dividing the sum of exhaled tidal breaths (cumulative exhaled volume (CEV)) by simultaneously measured functional residual capacity (FRC). An LCI of 7.5 and below is normal; values greater than 7.5 are abnormal. LCI is able to detect abnormalities in lung function earlier than more traditional modalities such as spirometry. OL-FAS. Data were planned to be presented as per parent study reporting groups (i.e., Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA). Here, “n” signifies subjects who were evaluable in the specified parent study reporting group at OL Week 96.
    End point type
    Secondary
    End point timeframe
    From Parent Study Baseline to Week 96
    End point values
    ELX/TEZ/IVA
    Number of subjects analysed
    104
    Units: Index
    least squares mean (standard error)
        Placebo-ELX/TEZ/IVA (n=56)
    -1.74 ( 0.18 )
        ELX/TEZ/IVA-ELX/TEZ/IVA (n=48)
    -2.35 ( 0.19 )
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Day 1 up to Week 100
    Adverse event reporting additional description
    The OL-SS included all subjects who had received at least 1 dose of study drug in the OLE study.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    25.1
    Reporting groups
    Reporting group title
    ELX/TEZ/IVA
    Reporting group description
    Subjects 6 to <12 year of age and weighing <30 kg at Day 1 received ELX 100 mg/TEZ 50 mg /IVA 75 mg as FDC tablets in the morning and IVA as mono tablet in the evening and those weighing ≥30 kg at Day 1 received ELX 200 mg/TEZ 100 mg /IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 96 weeks. Doses were adjusted upward with subsequent changes in weight. Subjects ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 96 weeks.

    Serious adverse events
    ELX/TEZ/IVA
    Total subjects affected by serious adverse events
         subjects affected / exposed
    13 / 120 (10.83%)
         number of deaths (all causes)
    0
         number of deaths resulting from adverse events
    Investigations
    Blood glucose increased
         subjects affected / exposed
    1 / 120 (0.83%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Injury, poisoning and procedural complications
    Head injury
         subjects affected / exposed
    1 / 120 (0.83%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    General disorders and administration site conditions
    General physical health deterioration
         subjects affected / exposed
    1 / 120 (0.83%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    Constipation
         subjects affected / exposed
    1 / 120 (0.83%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Ileus paralytic
         subjects affected / exposed
    1 / 120 (0.83%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Enteritis
         subjects affected / exposed
    1 / 120 (0.83%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Steatorrhoea
         subjects affected / exposed
    1 / 120 (0.83%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    1 / 120 (0.83%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal and urinary disorders
    Haematuria
         subjects affected / exposed
    1 / 120 (0.83%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Pneumonia staphylococcal
         subjects affected / exposed
    1 / 120 (0.83%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pneumonia pseudomonal
         subjects affected / exposed
    1 / 120 (0.83%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infective pulmonary exacerbation of cystic fibrosis
         subjects affected / exposed
    2 / 120 (1.67%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Bacterial disease carrier
         subjects affected / exposed
    1 / 120 (0.83%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Metabolism and nutrition disorders
    Diabetes mellitus inadequate control
         subjects affected / exposed
    1 / 120 (0.83%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Weight gain poor
         subjects affected / exposed
    1 / 120 (0.83%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    ELX/TEZ/IVA
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    118 / 120 (98.33%)
    Investigations
    Staphylococcus test positive
         subjects affected / exposed
    9 / 120 (7.50%)
         occurrences all number
    12
    SARS-CoV-2 test positive
         subjects affected / exposed
    12 / 120 (10.00%)
         occurrences all number
    13
    Bacterial test positive
         subjects affected / exposed
    7 / 120 (5.83%)
         occurrences all number
    10
    Aspartate aminotransferase increased
         subjects affected / exposed
    6 / 120 (5.00%)
         occurrences all number
    8
    Alanine aminotransferase increased
         subjects affected / exposed
    11 / 120 (9.17%)
         occurrences all number
    15
    Nervous system disorders
    Headache
         subjects affected / exposed
    45 / 120 (37.50%)
         occurrences all number
    106
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    48 / 120 (40.00%)
         occurrences all number
    85
    Fatigue
         subjects affected / exposed
    6 / 120 (5.00%)
         occurrences all number
    8
    Ear and labyrinth disorders
    Ear pain
         subjects affected / exposed
    8 / 120 (6.67%)
         occurrences all number
    13
    Immune system disorders
    Immunisation reaction
         subjects affected / exposed
    8 / 120 (6.67%)
         occurrences all number
    12
    Eye disorders
    Conjunctivitis allergic
         subjects affected / exposed
    7 / 120 (5.83%)
         occurrences all number
    12
    Gastrointestinal disorders
    Nausea
         subjects affected / exposed
    9 / 120 (7.50%)
         occurrences all number
    13
    Vomiting
         subjects affected / exposed
    24 / 120 (20.00%)
         occurrences all number
    42
    Abdominal pain
         subjects affected / exposed
    27 / 120 (22.50%)
         occurrences all number
    44
    Abdominal pain upper
         subjects affected / exposed
    11 / 120 (9.17%)
         occurrences all number
    13
    Constipation
         subjects affected / exposed
    8 / 120 (6.67%)
         occurrences all number
    8
    Diarrhoea
         subjects affected / exposed
    15 / 120 (12.50%)
         occurrences all number
    22
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    62 / 120 (51.67%)
         occurrences all number
    163
    Nasal congestion
         subjects affected / exposed
    13 / 120 (10.83%)
         occurrences all number
    15
    Oropharyngeal pain
         subjects affected / exposed
    32 / 120 (26.67%)
         occurrences all number
    51
    Productive cough
         subjects affected / exposed
    17 / 120 (14.17%)
         occurrences all number
    30
    Rhinorrhoea
         subjects affected / exposed
    22 / 120 (18.33%)
         occurrences all number
    50
    Musculoskeletal and connective tissue disorders
    Pain in extremity
         subjects affected / exposed
    9 / 120 (7.50%)
         occurrences all number
    12
    Infections and infestations
    Bacterial disease carrier
         subjects affected / exposed
    8 / 120 (6.67%)
         occurrences all number
    11
    COVID-19
         subjects affected / exposed
    70 / 120 (58.33%)
         occurrences all number
    78
    Hordeolum
         subjects affected / exposed
    10 / 120 (8.33%)
         occurrences all number
    12
    Infective pulmonary exacerbation of cystic fibrosis
         subjects affected / exposed
    19 / 120 (15.83%)
         occurrences all number
    27
    Influenza
         subjects affected / exposed
    11 / 120 (9.17%)
         occurrences all number
    12
    Nasopharyngitis
         subjects affected / exposed
    54 / 120 (45.00%)
         occurrences all number
    115
    Viral upper respiratory tract infection
         subjects affected / exposed
    13 / 120 (10.83%)
         occurrences all number
    17
    Upper respiratory tract infection
         subjects affected / exposed
    37 / 120 (30.83%)
         occurrences all number
    65
    Rhinitis
         subjects affected / exposed
    29 / 120 (24.17%)
         occurrences all number
    50
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    6 / 120 (5.00%)
         occurrences all number
    9

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 21:27:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA